Heavy Chain Only Antibodies (HCAbs)
- Endogenous murine antibody expression eliminated
- Human (or other mammalian) transgenes introduced, w/o CH1
- Antigen challenge results in affinity matured HCAbs
- Recovery from B cells or plasma cells (hybridoma or direct cDNA expression cloning)
HCAb Transgenic Mice Transgene
HCAb Platform Evaluation
Potent HCAbs raised against a range of proteins including
- cytokines,
- bacterial and
- viral targets
HCAbs isolated via:
- expression cloning,
- hybridomas,
- phage display
Consistent isolation of HCAbs with affinities in the high pMolar to nMolar range
HCAb and derived Vh Profiles:
- Soluble
- Do not form aggregates in vitro
- HCAbs have PK characteristics in vivo comparable to human H2L2 antibodies
HCAb & VH domains: Solubility & Aggregation
HCAb Platform: Applications
HCAbs can be used directly as simplified alternatives to conventional antibodies
The VH domains from HCAbs can yield “second generation” antibody-like therapeutics
- Bispecific antibodies
- Tetravalent antibodies
Harbour offers fully human HCAbs derived in vivo in transgenic mice
- High affinity
- Soluble
- Stable
Harbour has a broad, robust patent portfolio covering human heavy chain rodent technology and human heavy chain constructs, to include six US Patents, three European Patents and numerous other patents and pending applications around the world. Harbours HCAb mice technology is covered by US and several international issued and pending patent rights.
BiSpecific BiValent HCAb
Tetravalent human Ab are soluble and do not aggregate